Tislelizumab & Tremelimumab Among Latest Filings In EU
The sponsors of two monoclonal antibody products, tislelizumab and tremelimumab, are each seeking marketing approval for more than one indication.
You may also be interested in...
Pharming’s leniolisib for treating the rare immunodeficiency APDS is among the new drugs that the European Medicines Agency has started reviewing for potential EU marketing approval.
Santhera Pharmaceuticals’ vamorolone for treating Duchenne muscular dystrophy is among the latest medicines that have been submitted for review for potential pan-EU approval.
Fresenius Kabi’s tocilizumab biosimilar candidate is among the latest medicines that have been submitted for review for potential pan-EU approval.